Table 3.
The discriminatory power (C-index) of different models in the training and validation cohorts.
| Model | Author | Combination | Training cohort | Validation cohort |
|---|---|---|---|---|
| C-index (95%CI) | C-index (95%CI) | |||
| Model A (3) | Sofiane Bendifallah et al. | Only classical clinicopathological parameters: pathological grade, LVSI, myometrial invasion, et al. | 0.80 (0.75–0.85) | 0.86 (0.81–0.91) |
| Model B (28) | Jisun Lee et al. | Classical clinicopathological parameters + serological markers: pathological grade, myometrial invasion + serum CA125 | 0.80 (0.75–0.84) | 0.84 (0.77–0.90) |
| Model C (15) | Varol Gülseren et al. | Only immunohistochemical markers: Ki67, ER, PR, P53 | 0.79 (0.74–0.84) | 0.73 (0.64–0.81) |
| Model D (11) | Bingyi Yang et al. | Immunohistochemical markers + serological markers: PR, Ki67 + serum CA125 | 0.77 (0.73–0.82) | 0.71 (0.62–0.79) |
| Model E (29) | Marcos Ballester et al. | Classical clinicopathological parameters + Immunohistochemical markers: pathological type and grade, LVSI, myometrial invasion + ER, PR | 0.85 (0.81–0.89) | 0.87 (0.82–0.93) |
| Model proposed in this study | Classic clinicopathological parameters + serological markers + immunohistochemical markers: histological grade, LVSI, myometrial invasion + serum CA125 + Ki67, ER, P53 | 0.90 (0.87–0.94) | 0.91 (0.86–0.96) |
LVSI, lymphovascular space invasion; ER, estrogen receptor; PR, progesterone receptor.